Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2026-05-22 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于向香港联交所递交H股发行及上市申请并刊发申请资料的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement by the company that it has submitted an application to the Hong Kong Stock Exchange for issuance and listing of H shares and has published the related application materials. It is specifically notifying investors about a new share issue and capital change (H‐share issuance and listing). This fits the Share Issue/Capital Change category (SHA).
2026-05-22 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is a legal opinion letter by the company’s lawyers reviewing the convening, procedures, and actual voting results of the 2025 annual shareholders’ meeting. It provides detailed vote tallies and percentages for each agenda item, corresponding to a formal declaration of voting results. This matches the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-13 Chinese
神州细胞2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the resolutions of the 2025 Annual General Meeting, detailing meeting attendance, individual voting results, and percentages for each proposal. It provides official voting results rather than presenting any financial statements or management discussion. This matches the description for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-13 Chinese
神州细胞关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨召开2026年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in a 2025 annual pharmaceutical industry collective performance explanation meeting and the company's own 2026 first quarter earnings explanation meeting. It provides details about the meeting time, location, participants, and how investors can participate and ask questions. It references that the 2025 annual report and 2026 first quarter report have already been disclosed on the exchange website. The document does not contain actual financial statements or detailed financial data but rather announces the upcoming earnings explanation meeting and how investors can engage. The document length is short (1535 characters) and it serves as a notice for an investor presentation event rather than the presentation itself or a full report. Therefore, the best classification is Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, albeit in announcement form for an interactive session. Confidence is high given the clear description of the event and its purpose.
2026-04-29 Chinese
神州细胞2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled as "2025年年度股东会会议资料" which translates to "2025 Annual General Meeting (AGM) Meeting Materials" for Beijing SinoCellTech. It contains detailed information about the AGM including meeting notices, agenda, proposals to be voted on, voting procedures, and legal compliance. The document includes multiple agenda items such as approval of the 2025 annual report, board work report, profit distribution plan, director remuneration, related party transactions, audit firm appointment, and governance matters. It also includes detailed explanations of these proposals and references to other reports published elsewhere. The document is comprehensive and clearly intended as the materials shared during the Annual General Meeting. It is not the annual report itself, nor a brief announcement or voting results. The length (15,000 characters) and content confirm it is the AGM presentation materials. Therefore, the correct classification is AGM Information (AGM-R).
2026-04-29 Chinese
神州细胞关于新增募投项目实施主体后签订募集资金专户存储四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a four-party supervision agreement for the special account storage of raised funds following the addition of a new project implementation entity. It details the fundraising amount, the establishment and management of the special account, and the regulatory compliance measures. The text references regulatory approvals, fundraising specifics, and supervisory agreements but does not contain financial statements or detailed financial performance data. The document length is 3353 characters, which is relatively short and consistent with an announcement rather than a full report. It is not a full annual or interim report, audit report, or earnings release. It is not a proxy statement or voting result announcement. The content focuses on capital raising and fund management updates, specifically the signing of agreements and account opening related to fundraising. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.